Akero aims to develop and deliver transformational medicines to patients with high unmet medical need. Akeroâs current focus is advancing our lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis). Akero is led by industry veterans with decades of experience delivering innovative medicines to patients. We are united in our commitment to developing transformational new therapies for NASH and other serious metabolic diseases. Source
No articles found.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (â...
Lantheus Holdings, Inc. is the parent company o...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
Love Goodly is on a mission to help women love their bodiesâŚ.and feel good about...
Love Goodly is on a mission to help women love ...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.